Everolimus/Moderate CYP3A4; P-gp Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your liver processes everolimus.
What might happen:
The amount of everolimus in your blood may increase and cause more side effects than normal.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to check the amount of medicine in your blood.Let your doctor know right away if you have a new or worsening cough, shortness of breath, difficulty breathing, wheezing, fever, chills, or do not feel well.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Afinitor (everolimus) US prescribing information. Novartaris Pharmaceuticals Corporation Sept, 2017.
- 2.Covera-HS (verapamil hydrochloride) US prescribing information. G.D. Searle LLC September, 2017.
- 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
- 4.Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx August 18, 2011.
- 5.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..